Green D, Muller H P
Thromb Haemost. 1978 Jun 30;39(3):689-94.
The aggregation of platelets by the antibiotic, ristocetin, requires a plasma cofactor (VIII:vWF) and one or more specific binding sites on the platelet membrane. The interaction between VII:vWF and the platelet was examined using VIII:vWF labelled with 125I. In the presence of ristocetin (1.5 mg/ml), from 70 to 90% of the 125I-VIII:vWF became platelet-bound. By contrast, only 21% was bound with thrombin (2.5 microgram/ml), and 2.2% with buffer alone. Fractionation of the platelets revealed that peak radioactivity was present in the membrane fraction. Treatment of ristocetin-reacted platelets with either chymotrypsin, 100 microgram/ml, or trypsin, 75 microgram/ml, resulted in the partial release of the membrane-bound radioactivity. It is concluded that VIII:vWF binds to the platelet membrane in the presence of ristocetin.
抗生素瑞斯托霉素引起的血小板聚集需要一种血浆辅助因子(VIII:vWF)以及血小板膜上一个或多个特异性结合位点。使用用125I标记的VIII:vWF研究了VII:vWF与血小板之间的相互作用。在存在瑞斯托霉素(1.5毫克/毫升)的情况下,70%至90%的125I-VIII:vWF与血小板结合。相比之下,仅21%与凝血酶(2.5微克/毫升)结合,仅2.2%与单独的缓冲液结合。血小板分级分离显示膜级分中存在放射性峰值。用100微克/毫升的胰凝乳蛋白酶或75微克/毫升的胰蛋白酶处理经瑞斯托霉素作用的血小板,导致膜结合放射性部分释放。得出的结论是,在瑞斯托霉素存在的情况下,VIII:vWF与血小板膜结合。